What is 35Pharma?
35Pharma is a clinical-stage biopharmaceutical company focused on pioneering innovative therapeutics within the TGF-beta superfamily, with a particular emphasis on Activin and GDF biology. The company's lead candidate, HS235, is currently undergoing clinical development for critical conditions such as pulmonary hypertension, heart failure, and obesity, areas marked by significant unmet medical needs. By employing advanced protein engineering techniques, 35Pharma designs highly selective and potent multi-specific ligand traps, a strategy aimed at accelerating clinical trial timelines and enhancing therapeutic efficacy. The company's experienced team is dedicated to advancing complex biologics through the development pipeline.
How much funding has 35Pharma raised?
35Pharma has raised a total of $53M across 1 funding round:
Series C
$53M
Series C (2024): $53M with participation from Vivo Capital, Frazier Life Sciences Management, and Deep Track Capital
Key Investors in 35Pharma
Vivo Capital
Vivo Capital, founded in 1996, is a global healthcare investment firm based in Palo Alto, California, with a focus on private and public equity, as well as venture capital investments within the healthcare sector.
Frazier Life Sciences Management
Frazier Life Sciences is a prominent biotech investment firm that utilizes both venture and public strategies to partner with and build companies developing novel therapeutics. They have managed over $5.3 billion in capital since 2015 and are known for their collaborative approach and deep industry expertise.
Deep Track Capital
Deep Track Capital is an investment firm located in Greenwich, Connecticut, specializing exclusively in the life sciences industry, with a particular focus on biotechnology investments.
What's next for 35Pharma?
The recent major enterprise-level funding positions 35Pharma for accelerated growth and the advancement of its therapeutic pipeline. This strategic capital infusion is expected to fuel further clinical development of HS235 and potentially expand research into other TGF-beta superfamily targets. The company's focus on precision biologics and addressing significant unmet medical needs suggests a trajectory towards pivotal trials and potential commercialization, marking a critical phase in its evolution as a biopharmaceutical innovator. Continued investment in its experienced team and advanced platform will be key to navigating the complexities of drug development and regulatory approval.
See full 35Pharma company page
